EQS-News: Successful completion of a record year for Redcare Pharmacy: growth 49%, adj. EBITDA margin up 3.7pp to 3%; guidance achieved in all its elements.
Successful completion of a record year for Redcare Pharmacy: growth 49%, adj.
- Successful completion of a record year for Redcare Pharmacy: growth 49%, adj.
- EBITDA margin 3% for full year 2023, +3.7pp vs. 2022, with major improvements in both DACH and International segments.
- Full-year guidance for 2024: continuation of both fast sales growth (30-40%) and solidly positive margins (adj.
- Following positive margins in all four quarters, (iii) the adjusted EBITDA margin for the full year was 3% (guidance range of 1.5% to 3%).